Phase I Study of Immunotoxin, MR1-1
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Durham |
| State: |
|
North Carolina |
| Zip Code: |
|
27710 |
| Conditions: |
|
Supratentorial Malignant Brain Tumor |
| Purpose: |
|
Purpose of the study:
Primary Objective: Determine the maximum tolerated dose (MTD) and dose limiting toxicity
(DLT) of MR1-1KDEL when delivered intracerebrally by convection-enhanced delivery (CED) in
patients with supratentorial malignant brain tumors.
Secondary Objective: Document any radiographic responses associated with intracerebral CED
of MR1-1KDEL.
Hypothesis: The investigators believe that MR1-1KDEL will be an effective anti-tumor agent
for patients with supratentorial malignant brain tumors when delivered by CED.
Design & procedures: This protocol is designed primarily to determine the MTD and DLT of a
novel, tumor-specific immunotoxin, MR1-1KDEL. MR1-1KDEL will be delivered intracerebrally
by CED using 2 intracerebral catheters with at least one catheter placed within the
enhancing portion of the tumor. 124I-labeled albumin will be co-infused with gadolinium and
PET and MRI images will be obtained at the conclusion of the infusion to monitor volume of
drug distribution and leakage into the CSF space.
Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng)
which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5
mL/h from each of two to four catheters. A total of 144 mLs of drug solution will be
delivered over 72 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug
concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be
doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4
μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL
(38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg). At least 3 patients will be
enrolled in each cohort. All patients in a given cohort will be observed for at least two
weeks following infusion of the study drug before patients in the next cohort are treated.
If no patients in a given cohort experience a DLT, the dose will be escalated in the next
cohort. If 1 out of 3 patients in a given cohort experience DLT, 3 additional patients will
be entered in that cohort. If 2 patients develop a DLT in any cohort of 3 or 6 patients,
the previous dose will be declared the MTD. Patients will be followed at 1, 3, 6, 9, 12
month intervals for toxicity and adverse events, radiographic response, and survival.
Patients will be off study when progressive disease is documented.
Risk/benefit assessment: This is an experimental study and unforeseeable or unexpected risks
may be involved.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Residual, progressive, or recurrent supratentorial malignant brain tumor based on
imaging studies with measurable disease (>0.5cm).
- Patient will have completed some form of radiation therapy prior to toxin treatment.
- Karnofsky Performance score >70.
- The presence of the target antigen, EGFRvIII, must be identified on tumor tissue by
immunohistochemistry.
- Platelet count > 100 x 109/L; PTT and PT < 120% of normal range.
- Creatinine < 120% of normal range.
- Total bilirubin, SGOT, SGPT,alkaline phosphatase < 300% of normal range.
Exclusion Criteria:
- Patients who are pregnant, breast-feeding, or unwilling to practice an effective
method of birth control.
- Patients with known potentially anaphylactic allergic reactions to iodine or
gadolinium-DTPA.
- Patients who cannot undergo MRI due to obesity or to having certain metal in their
bodies (specifically pacemakers, infusion pumps, metal aneurysm clips, metal
prostheses, joints, rods or plates).
- Patients that have not recovered from the toxic effects of prior chemotherapy and/or
radiation therapy.
- Patients with an impending, life-threatening cerebral herniation syndrome.
- Patients with subependymal or CSF disease.
- Patients who are under the age of 18 years.
|
| NCT ID: |
|
NCT01009866 |
| Primary Contact: |
|
Principal Investigator
Annick Desjardins, MD
Duke University Health System
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Durham, North Carolina 27710
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|